Manufacturing mesenchymal stromal cells for phase I clinical trials

被引：41

作者：

Hanley, Patrick J. ^{[1
,2
]}

Mei, Zhuyong ^{[1
,2
]}

Cabreira-Hansen, Maria da Graca ^{[3
]}

Klis, Mariola ^{[1
,2
]}

Li, Wei ^{[1
,2
]}

Zhao, Yali ^{[1
,2
]}

Durett, April G. ^{[1
,2
]}

Zheng, Xingwu ^{[4
]}

Wang, Yongping ^{[4
,5
]}

Gee, Adrian P. ^{[1
,2
]}

Horwitz, Edwin M. ^{[4
,5
]}

机构：

[1] Texas Childrens Hosp, Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA

[2] Methodist Hosp, Houston, TX 77030 USA

[3] St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX USA

[4] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA

[5] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

来源：

CYTOTHERAPY | 2013年 / 15卷 / 04期

基金：

美国国家卫生研究院;

关键词：

clinical trials; Good Manufacturing Practices; mesenchymal stromal cells; phase I trials; BONE-MARROW; STEM-CELLS; BLOOD; CHILDREN; CULTURE; THERAPY; LIVER;

D O I：

10.1016/j.jcyt.2012.09.007

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

Mesenchymal stromal cells (MSCs) are multipotent progenitor cells capable of differentiating into adipocytes, osteoblasts and chondroblasts as well as secreting a vast array of soluble mediators. This potentially makes MSCs important mediators of a variety of therapeutic applications. They are actively under evaluation for immunomodulatory purposes such as graft-versus-host disease and Crohn's disease as well as regenerative applications such as stroke and congestive heart failure. We report our method of generating clinical-grade MSCs together with suggestions gathered from manufacturing experience in our Good Manufacturing Practices facility.

引用

页码：416 / 422

页数：7

共 50 条

[41] Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trials
Lotfy, Ahmed
AboQuella, Noha M.
Wang, Hongjun
STEM CELL RESEARCH & THERAPY, 2023, 14 (01)
[42] Clinical Trials With Mesenchymal Stem Cells: An Update
Squillaro, Tiziana
Peluso, Gianfranco
Galderisi, Umberto
CELL TRANSPLANTATION, 2016, 25 (05) : 829 - 848
[43] Generation and characterization of mesenchymal stromal cells for clinical application
Sensebe, L.
ISBT SCIENCE SERIES, VOL 4, NO 1, STATE OF THE ART PRESENTATIONS, 2009, 4 (01): : 31 - 36
[44] MESENCHYMAL STROMAL CELLS AS A CLINICAL THERAPY FOR TISSUE REPAIR
Fogarty, J.
Sturm, M.
Carnley, B.
Prentice, D.
CYTOTHERAPY, 2018, 20 (05) : S37 - S37
[45] International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials
Galipeau, Jacques
Krampera, Mauro
Barrett, John
Dazzi, Francesco
Deans, Robert J.
Debruijn, Joost
Dominici, Massimo
Fibbe, Willem E.
Gee, Adrian P.
Gimble, Jeffery M.
Hematti, Peiman
Koh, Mickey B. C.
Leblanc, Katarina
Martin, Ivan
McNiece, Ian K.
Mendicino, Michael
Oh, Steve
Ortiz, Luis
Phinney, Donald G.
Planat, Valerie
Shi, Yufang
Stroncek, David F.
Viswanathan, Sowmya
Weiss, Daniel J.
Sensebe, Luc
CYTOTHERAPY, 2016, 18 (02) : 151 - 159
[46] Clinical Translation of Multipotent Mesenchymal Stromal Cells in Transplantation
Leuning, Danielle G.
Reinders, Marlies E. J.
de Fijter, Johannes W.
Rabelink, Ton J.
SEMINARS IN NEPHROLOGY, 2014, 34 (04) : 351 - 364
[47] Mesenchymal stromal cells: Getting ready for clinical primetime
Wobma, Holly
Satwani, Prakash
TRANSFUSION AND APHERESIS SCIENCE, 2021, 60 (01)
[48] Challenges and advances in clinical applications of mesenchymal stromal cells
Tian Zhou
Zenan Yuan
Jianyu Weng
Duanqing Pei
Xin Du
Chang He
Peilong Lai
Journal of Hematology & Oncology, 14
[49] A potency assay for clinical grade mesenchymal stromal cells
Galleu, A.
Weng, L.
Marigo, I.
Dazzi, F.
BONE MARROW TRANSPLANTATION, 2013, 48 : S262 - S263
[50] Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities
Galipeau, Jacques
Sensebe, Luc
CELL STEM CELL, 2018, 22 (06) : 824 - 833

← 1 2 3 4 5 →